(Q27852806)

English

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.

scientific article

In more languages

Statements

scholarly article

1 reference

13 November 2016

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. (English)

1 reference

13 November 2016

1 reference

based on heuristic

inferred from title

author name string

S-H I Ou

1

0 references

P A Jänne

2

0 references

C H Bartlett

3

0 references

Y Tang

4

0 references

D-W Kim

5

0 references

G A Otterson

6

0 references

L Crinò

7

0 references

P Selaru

8

0 references

D P Cohen

9

0 references

J W Clark

10

0 references

G J Riely

11

0 references

publication date

February 2014

0 references

Annals of Oncology

0 references

25

0 references

415-22

0 references

2

0 references

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT572

21 January 2018

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT572

21 January 2018

Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT572

21 January 2018

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT572

21 January 2018

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT572

21 January 2018

Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT572

21 January 2018

Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT572

21 January 2018

Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT572

21 January 2018

Disease flare after treatment discontinuation in a patient with EML4-ALK lung cancer and acquired resistance to crizotinib.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT572

21 January 2018

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT572

21 January 2018

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT572

21 January 2018

Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT572

21 January 2018

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT572

21 January 2018

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT572

21 January 2018

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT572

21 January 2018

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT572

21 January 2018

Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT572

21 January 2018

Response to crizotinib rechallenge after initial progression and intervening chemotherapy in ALK lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT572

21 January 2018

Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT572

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27852806&oldid=1622614468"